Sarah Auclair

Scientist at Sanofi

Speaker

Early stage developability and manufacturing risk assessment is needed to ensure selection of well-behaved molecules. As the biologics pipeline begins to diversify with more complex protein therapeutics it may become essential to tailor our approach for each modality. Our developability workflow will be presented along with several case studies where our platform approach needed customization to fully assess the pre-candidates.